hers hims news - Search News

Novo Nordisk, Hims & Hers Health

Hims & Hers Stock Rises on Earnings and Planned Generic Version of Novo Nordisk Diabetes Drug

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo Nordisk’s diabetes drug as soon as 2025.It reported strong quarterly earnings. The stock rose 8.

Investopedia · 18h

Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.

Reuters on MSN · 1d

Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025. "We have already confirmed a core supplier for this addition and over the next few months expect to finish completing test and batch validation,

Barron's on MSN · 17h

Novo Nordisk Posts Solid Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. W

1don MSN

Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

19h

Hims & Hers stock could dive soon despite strong results

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

Hims & Hers Health, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Hims & Hers Health, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beat ...

Hims & Hers Health: Another Blowout Quarter Ignored

Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...

21h

Hims & Hers price target raised to $21 from $18 at Piper Sandler

Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...

Becker's Hospital Review17h

Hims & Hers to sell generic weight loss drug in 2025

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Seeking Alpha1d

Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...

Business Insider1d

Hims & Hers Health (HIMS) Gets a Hold from Truist Financial

Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health (HIMS – Research Report) today. The company’s shares closed yesterday at $20.76. According to TipRanks, ...

Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details

Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...

Stocktwits on MSN1d

Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 Performance

Hims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results